S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Forecast, Price & News

$4.02
-0.12 (-2.90%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.94
$4.36
50-Day Range
$2.12
$4.47
52-Week Range
$1.81
$13.73
Volume
531,998 shs
Average Volume
1.87 million shs
Market Capitalization
$160.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
372.6% Upside
$19.00 Price Target
Short Interest
Healthy
1.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Oramed Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$293,240 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

479th out of 983 stocks

Pharmaceutical Preparations Industry

231st out of 486 stocks


ORMP stock logo

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

ORMP: Advancing Development Efforts in China
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
8-K: ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals, Inc
H.C. Wainwright Reaffirms Their Hold Rating on Oramed Pharm (ORMP)
Oramed Pharmaceuticals Inc. (ORMP.TA)
Oramed Pharmaceuticals Issues Shareholder Update
See More Headlines

ORMP Price History

ORMP Company Calendar

Last Earnings
3/06/2023
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+372.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-36,560,000.00
Net Margins
-1,093.27%
Pretax Margin
-1,130.85%

Debt

Sales & Book Value

Annual Sales
$2.70 million
Book Value
$3.75 per share

Miscellaneous

Free Float
37,265,000
Market Cap
$160.92 million
Optionable
Optionable
Beta
1.78

Key Executives

  • Nadav KidronNadav Kidron
    President, Chief Executive Officer & Director
  • Joshua Hexter
    Chief Operating & Business Officer
  • Miriam Kidron
    Director & Chief Scientific Officer
  • Michael Rabinowitz
    Chief Commercial Officer
  • Zach Herschfus
    Head-Investor Relations













ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares.
View ORMP analyst ratings
or view top-rated stocks.

What is Oramed Pharmaceuticals' stock price forecast for 2023?

3 brokers have issued 12 month price objectives for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 372.6% from the stock's current price.
View analysts price targets for ORMP
or view top-rated stocks among Wall Street analysts.

How have ORMP shares performed in 2023?

Oramed Pharmaceuticals' stock was trading at $12.03 at the start of the year. Since then, ORMP stock has decreased by 66.6% and is now trading at $4.02.
View the best growth stocks for 2023 here
.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ORMP earnings forecast
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its earnings results on Monday, March, 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $0.75 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 19.46% and a negative net margin of 1,093.27%.

What ETFs hold Oramed Pharmaceuticals' stock?

ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and BlueStar Israel Technology ETF (ITEQ) and

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.41%), Two Sigma Investments LP (1.26%), Two Sigma Advisers LP (1.11%), JPMorgan Chase & Co. (0.43%), XTX Topco Ltd (0.38%) and Susquehanna International Group Ltd. (0.28%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov.
View institutional ownership trends
.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $4.02.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $160.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -